Galderma’s nemolizumab sets new standard in prurigo nodularis treatment with OLYMPIA 1 trial success
Galderma’s latest clinical trial has unveiled a significant breakthrough in treating prurigo nodularis, a chronic neuroimmune skin condition characterized by relentless itching and thickened skin ... Read More
Galderma’s breakthrough drug Nemluvio gains rapid FDA approval for severe itch condition
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving Nemluvio (nemolizumab) for the treatment of prurigo nodularis in adults. ... Read More